Ironwood Pharmaceuticals says a patient survey found eliminating total parenteral nutrition is the top priority for future short bowel syndrome therapies. The r

Ironwood Pharmaceuticals says a patient survey found eliminating total parenteral nutrition is the top priority for future short bowel syndrome therapies. The result underscores how patient preferences are shaping SBS drug research and development.